Correlation Between Conduit Pharmaceuticals and Seres Therapeutics
Can any of the company-specific risk be diversified away by investing in both Conduit Pharmaceuticals and Seres Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Conduit Pharmaceuticals and Seres Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Conduit Pharmaceuticals and Seres Therapeutics, you can compare the effects of market volatilities on Conduit Pharmaceuticals and Seres Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Conduit Pharmaceuticals with a short position of Seres Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Conduit Pharmaceuticals and Seres Therapeutics.
Diversification Opportunities for Conduit Pharmaceuticals and Seres Therapeutics
0.64 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Conduit and Seres is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Conduit Pharmaceuticals and Seres Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Seres Therapeutics and Conduit Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Conduit Pharmaceuticals are associated (or correlated) with Seres Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Seres Therapeutics has no effect on the direction of Conduit Pharmaceuticals i.e., Conduit Pharmaceuticals and Seres Therapeutics go up and down completely randomly.
Pair Corralation between Conduit Pharmaceuticals and Seres Therapeutics
Considering the 90-day investment horizon Conduit Pharmaceuticals is expected to under-perform the Seres Therapeutics. In addition to that, Conduit Pharmaceuticals is 1.05 times more volatile than Seres Therapeutics. It trades about -0.26 of its total potential returns per unit of risk. Seres Therapeutics is currently generating about 0.03 per unit of volatility. If you would invest 114.00 in Seres Therapeutics on September 3, 2024 and sell it today you would lose (16.00) from holding Seres Therapeutics or give up 14.04% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Conduit Pharmaceuticals vs. Seres Therapeutics
Performance |
| Timeline |
| Conduit Pharmaceuticals |
| Seres Therapeutics |
Conduit Pharmaceuticals and Seres Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Conduit Pharmaceuticals and Seres Therapeutics
The main advantage of trading using opposite Conduit Pharmaceuticals and Seres Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Conduit Pharmaceuticals position performs unexpectedly, Seres Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will offset losses from the drop in Seres Therapeutics' long position.| Conduit Pharmaceuticals vs. DiaMedica Therapeutics | Conduit Pharmaceuticals vs. Lyra Therapeutics | Conduit Pharmaceuticals vs. Centessa Pharmaceuticals PLC |
| Seres Therapeutics vs. DiaMedica Therapeutics | Seres Therapeutics vs. Lyra Therapeutics | Seres Therapeutics vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |